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Background: Drug shortages are a potential threat to public health. Reliable data on
drug shortages is limited. The objective was to examine the extent and nature of potential
drug shortages signaled by authorities and pharmacy practice in the Netherlands
Materials andMethods: The primary working systems of Dutch authorities (Medicines
Evaluation Board and Health and Youth Care Inspectorate) and the archives of pharmacy
practice (Royal Dutch Pharmacists Association) from 2012 to 2015 were searched for
number, characteristics, overlap, and date of signals on potential drug shortages. Also,
the product characteristics of the potential drug shortages were analyzed from the two
different sources
Results: Authorities detected 2.6 times more signals on potential shortages than
pharmacy practice. Only 438 (8%) out of 5,731 potential drug shortages were detected
by both authorities and pharmacy practice. Signals were detected later by authorities
than by pharmacy practice, especially on potential permanent shortages (median
difference −180 days (IQR: −4 to −405 days)). Authorities detected by majority (72%)
signals related to permanent shortages with relative overrepresentation of rectal products
and anti-infectives for systemic use. In contrast, pharmacy practice detected by majority
(71%) signals related to temporary shortages with relative overrepresentation of ocular
and cutaneous products, anti-infectives for systemic use, products for sensory organs
and dermatologicals.
Conclusions: Authorities and pharmacy practice detected different signals on potential
drug shortages with little overlap. Combining data from both authorities and pharmacy
practice seems to be necessary in order to gain a more complete overview andmaximum
insight in potential drug shortages at a national level. Moreover, the finding that authorities
were informed later than pharmacy practice causes concerns in terms of opportunities
for authorities to assist pharmacy practice to find solutions for shortages.
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INTRODUCTION
Drug shortages are a potential threat to public health. According
to the World Health Organization, drug shortages are becoming,
if not are already, a global problem (Gray and Manasse, 2012;
WHO, 2016). Countries all over the world have reported drug
shortages and subsequent problems that affect both developing
and developed countries (Lynas, 2013; Quilty, 2014; Chen et al.,
2016; Rosa et al., 2016; De Weerdt et al., 2017). Shortages have
resulted in problems with medication such as errors, rationing,
delayed supply, and denial of treatment in some cases (Fox et al.,
2014; Vail et al., 2017). Shortages not only impact patients; health
care professionals are confronted with lack of information on
shortages and need to find proper solutions, causing pressure
on primary and hospital care (McCartney, 2015), as well as
an increase in costs (Iacobucci, 2017). Reliable data on drug
shortages is limited. Scientific publications are mainly based
on narrative reviews (De Weerdt et al., 2017), survey results
(Pauwels et al., 2015), or anecdotal evidence from studies of
specific drugs (Malone et al., 2016). The growing problems due
to shortages have been addressed in public media as well (Koba,
2015; Fink, 2016). The media has especially focused on the
harmful effects of shortages for patients.
When shortages occur, authorities struggle with whether and
how to intervene. In the United States, the Food and Drug
Administration (FDA) has received new and expanded regulatory
powers to respond to national shortages by the Food and Drug
Administration Safety and Innovation Act in 2011 (McCarthy,
2013). According to this act, a marketing authorization holder
(MAH) has to notify the FDA of a discontinuation or
interruption when it will lead to ameaningful supply interruption
of a drug that is life-supporting, life-sustaining, or intended for
use in the prevention or treatment of a debilitating disease or
condition. They have to notify the FDA at least six months in
advance or as soon as possible, but not later than five business
days after the start of discontinuation or interruption. If anMAH
fails to submit this information, letters are made public on the
website of the FDA (Food and Drug Food Drug Administration,
2015). It seems that these measures have had impact. The number
of shortages in the United States decreased by 24% in 2012 and by
60% in 2013, respectively (Fox et al., 2014). European legislation
states that “the holder of a marketing authorization for a medicinal
product . . . shall, within the limits of his responsibilities, ensure
appropriate and continued supplies of that medicinal product
to pharmacies” (The European Parliament the Council of the
European Union, 2011). The European Medicines Agency has
been involved in several drug shortages, in case the shortage
was linked to a safety concern and multiple Member States
were affected. However, most drug shortages are handled at
a national level by national competent authorities (European
Medicines Agency, 2013). In France, the French legislator chose
to introduce new measures to the law in January 2016 to fight
drug shortages. MAHs are now legally bound to ensure sustained
supply and stocks of drugs theymarket in France tomeet needs of
patients (Bocquet et al., 2017). In the Netherlands, the Medicines
Act of 2007 states that “a marketing authorization holder takes
care that a medicinal product with a marketing authorization is
in stock in sufficient amount for wholesalers and pharmacists”
and the MAH “must notify the authorities of interruption of
a medicine. Foreseen shortages must be reported 2 months in
advance and unforeseen as soon as possible” (Dutch Government,
2007). Despite this legislation, pharmacies face drug shortages
regularly, which makes it important to monitor these shortages
at a national level and to advise on potential solutions. The
Royal Dutch Pharmacists Association (KNMP) launched a public
website to inform pharmacists about new shortages and about
the status of ongoing shortages in 2004. Similar initiatives have
been launched inside (Bochenek et al., 2017) and outside the
EU. The University of Utah’s Drug Information Service (UUDIS),
for example, has a comparable website which is hosted by the
American Society of Health-System Pharmacists (ASHP) (Fox
et al., 2009).
All these initiatives to monitor and manage drug shortages,
legally bounded or not, show the critical importance of timely
and high-quality information on potential shortages throughout
the supply chain. Only when signals on potential drug shortages
are tagged in an efficient and adequate manner, authorities and
health care professionals can act accordingly. This study aims to
evaluate the added value of signals on potential shortages derived
from two different sources: authorities and pharmacy practice.
Therefore, we examined the extent and nature of potential drug
shortages signaled by authorities and pharmacy practice in the
Netherlands.
METHODS
Data Sources
We collected data on potential drug shortages in 2012–2015 from
the Dutch authorities and pharmacy practice. Authorities have
received mandatory reports from MAHs since the Medicines
Act of 2007. MAHs have to report foreseen shortages to the
Dutch Medicines Evaluation Board (MEB) 2 months in advance
and unforeseen shortages to the Dutch Health and Youth Care
Inspectorate (Inspectorate) as soon as possible. We retrieved data
from both of these authorities, thereby excluding duplicates.
Pharmacists, both hospital-based and community-based
pharmacists, have voluntarily reported shortages to the Royal
Dutch Pharmacists Association (Koninklijke Nederlandse
Maatschappij ter bevordering der Pharmacie, KNMP) since
2004. These reports from pharmacists best reflect shortages
experienced in pharmacy practice. Other professionals and
patients can also report, although this occurs less frequently.
MAHs can also report shortages here but are not obliged to do
so. We retrieved data from pharmacy practice from the archives
of the KNMP. KNMP publishes the information, after validating
with the MAH, on a public website (farmanco.knmp.nl) when
the medicinal product is nationally unavailable for at least 2
weeks. KNMP also advises on potential solutions, which were
publicly available during the study period.
Definitions
We defined a signal on a potential shortage at the level of
products with a marketing authorization (MA) for human
use thus excluding veterinary drugs. Homeopathic and herbal
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FIGURE 1 | Number of new signals on potential shortages per calendar year.
drugs were also excluded as well as unregistered products such
as raw materials, pharmacy preparations and food additives.
We excluded signals on parallel import products since parallel
importers are not legally obliged to notify the authorities on
potential shortages. We defined a signal to be overlapping by two
criteria. First, the signal was related to the same MA. Second,
for a potential temporary shortage the signal had to be detected
by authorities 30 days before or after the signal was detected
by pharmacy practice. For a potentially permanent shortage the
signal had to be detected by both authorities and pharmacy
practice at any point during the study period.
Data Analysis
We analyzed the signals on potential shortages per calendar
year, distinguishing between signals on permanent shortages
(withdrawals) and temporary shortages (supply interruptions).
When products were permanent in shortage after being
temporary in shortage, we considered this a permanent shortage.
We also distinguished between signals on marketed and not
marketed products in the Netherlands based on the national drug
database (G-Standaard) (Z-index1). Everymedicinal product that
is actually marketed is listed in this database. We analyzed the
overlap in signals between authorities and pharmacy practice.
For overlapping signals on potentially permanent shortages, we
plotted the date the shortage signal was detected by authorities
vs. the date it was detected by pharmacy practice. Signals on
temporary shortages were excluded from this latter analysis, since
we defined a time frame as part of the definition for overlap.
We calculated the median difference in time, as well as the
1Z-index About Z Index (2018). [Online]. Available: https://www.z-index.nl/
english [Accessed July, 2018]
interquartile range (IQR). All marketed products which were
signaled for a potential shortage, were categorized by their route
of administration according to the Standard Terms of the EDQM
(European Directorate for the Quality of Medicines HealthCare,
2016) and by their Anatomical Therapeutic Chemical (ATC) class
of the WHO (WHO Collaborating Centre for Drug Statistics
Methodology ATC - Structure, 2018). These categories were
compared to the overall characteristics of the products on the
Dutch market (data obtained from G-Standaard).
RESULTS
Authorities detected signals on 4,154 potential shortages; 2,128
(51%) signals were related to products marketed in the
Netherlands. Most signals (n = 2,991; 72%) were on permanent
shortages. The overall number of signals to authorities decreased
during the study period from 1,366 to 880 per year (Figure 1),
despite an increase in the number of signals on temporary
shortages. Pharmacy practice detected signals on 1,577 potential
shortages (Figure 2). Most signals (n = 1,140; 72%) were for
temporary shortages. The overall number of signals to pharmacy
practice increased during the study period from 340 to 495
per year due to an increase in signals on temporary shortages
(Figure 1). During the study period, authorities detected in total
2.6 times more signals on potential shortages than pharmacy
practice.
Of a total of 5,731 signals on potential shortages detected by
both authorities and pharmacy practice during the study period,
only 438 (8%) overlapped (Figure 2). Overlapping signals were
for temporary shortages (n = 251; 57%) and for permanent
shortages (n = 187, 43%). The median difference in reporting
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FIGURE 2 | Overlap in signals on potential shortages between authorities and pharmacy practice.
dates for permanent shortages between authorities and pharmacy
practice was −180 days (interquartile range [IQR]: −8 to −405
days), meaning that pharmacy practice detected the overlapping
signals earlier than authorities (Figure 3). Overlapping signals
on temporary shortages were also detected by pharmacy practice
before they were detected by authorities, with amedian difference
of−1 day (interquartile range [IQR]: 23 to−203 days).
Characteristics of Signals
The products for which signals were detected by authorities
and pharmacy practice differed in route of administration and
showed partial similarity regarding their ATC class (Figures 4,
5). Authorities detected signals more frequently for rectal
products (1.2 times as compared to overall market share) and
anti-infectives for systemic use (1.4 times). Pharmacy practice
detected signals more frequently for ocular (1.8 times) and
cutaneous (1.7 times) products and anti-infectives for systemic
use (2.1 times), products for sensory organs (1.8 times), and
dermatologicals (1.6 times).
DISCUSSION
Our results show totally different perspectives on potential drug
shortages when signals from authorities and pharmacy practice
are compared. Comparing both sources, we found a very small
overlap in signals (8%), different types and characteristics of the
affected products and a differential timing of signals. Whereas
authorities faced a decrease in number of signals over time,
pharmacy practice faced an increase in number of signals. For
authorities, a typical signal as identified in this study would be
the permanent shortage of a rectal product or an anti-infective
for systemic use. For pharmacy practice, a typical signal would be
a temporary shortage of an ocular product or an anti-infective
for systemic use. Signals to authorities were likely detected by
pharmacy practice as well, but the latter detected it earlier. Signals
to pharmacy practice may have been detected by authorities as
well, but this would not be very likely.
Authorities detected signals on permanent shortages much
later than pharmacy practice. Although signals on temporary
shortages were detected with a median difference of 1
day, results show a larger variation toward the delay to
authorities (Q3 = −203 days) than delay to pharmacy practice
(Q1 = −23 days). Since early signaling to authorities is
considered critical in preventing and mitigating a drug shortage
(Fox et al., 2014), authorities were insufficiently able to
intervene during problems in pharmacy practice. Combining
both databases gives much more insight and potential to timely
action.
The major strength of this study is the direct comparison
between signals on potential shortages to authorities and to
pharmacy practice for a study period of several years. Authorities
in many countries may have data on drug shortages but only
few countries collect data from pharmacy practice at a national
level and have historical data. It could be argued that data from
pharmacy practice mainly relate to local shortages. However,
90% of these signals in our study were confirmed by the MAH
as a shortage at a national level. The best available data on
drug shortages originate from the American UUDIS/ASHP on
pharmacy practice and from the FDA authority (Fox et al.,
2009, 2014). These data are comparable to the datasets in the
Netherlands since the Dutch as well as the American data
report shortages at a national level which have been confirmed
by MAHs (American Society of Health-System Pharmacists,
2018; Food Drug Administration, 2018). A direct comparison
between the American databases on shortages was only made
for a short study period, January 2013 through March 2013.
FDA and UUDIS identified a different number of shortages;
17 and 39 respectively. Only 8 shortages overlapped and 5
of these 8 shortages were signaled 6 to 50 days earlier by
FDA than UUDIS (US Government Accountablility Office,
2016). UUDIS and FDA have different perspectives on the
definition of a shortage, organizations’ objectives and the data
at their disposal, resulting in different numbers (Wosinska and
Jensen, 2015; US Government Accountablility Office, 2016).
The UUDIS found (Chen et al., 2016) that 55% of their
shortages affected parenteral products and the most common
classes of drugs were central nervous system agents (17%)
and anti-infective agents (14%). These latter results differ
from our findings, which may be explained by the fact that
we studied signals on potential shortages, whereas UUDIS
studied shortages. Also, shortages reported to the UUDIS
are published on a website which is hosted by the ASHP
which represents pharmacists who serve in hospital settings.
As expected UUDIS signals relatively more hospital products.
KNMP detected signals from hospital-based and community-
based pharmacists.
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FIGURE 3 | Date of signal by authorities vs. pharmacy practice for potential permanent shortages.
FIGURE 4 | Signals on potential shortages characterized by route of administration (indexed for market share; at 1.0 the proportion of signaled products with this
route of administration is equal to the proportion of products on the Dutch market with this route of administration.
This study clearly shows a difference in signals on potential
shortages detected by authorities and pharmacy practice. Half
of this gap (2,026 signals; 51%) is due to signals on products
which were never marketed in the Netherlands and therefore
could not affect pharmacy practice. Another part of this gap is
probably explained by the different sources of signals, perspective
of authorities and pharmacy practice and their definition of
a shortage. Authorities detect signals from MAHs whereas
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FIGURE 5 | Signals on potential shortages characterized by ATC class (indexed for market share; at 1.0 the proportion of signaled products with this ATC class is
equal to the proportion of products on the Dutch market with this ATC class).
pharmacy practice detects signals from pharmacists. MAHs may
be reluctant to signal potential drug shortages due to logistical
and marketing reasons, since potential shortages might disrupt
market shares and could be regarded as a negative message
to communicate. Not reporting of mandatory signals has not
been sanctioned by authorities so far, since they have been
focusing primarily on finding solutions for shortages and not on
reporting (Dutch Government, Ministry of Health, Welfare and
Sport, 2017). Pharmacists may be reluctant to signal potential
drug shortages in view of the voluntary nature of the system.
Pharmacists probably signaled potential shortages with a large
practical impact (to be solved by replacing with a different
active substance) more frequently. Potential shortages with less
impact (to be solved by replacing with a product with the
same therapeutic active substance) were probably signaled less
frequently.
Whereas authorities focus on shortages with patient impact
at the population level, pharmacy practice handles continuity
of care at the patient level. It is known that the definition
of a drug shortage depends on the type of organization (De
Weerdt et al., 2015) and can be interpreted differently (Barlas,
2014). In addition, not all signals become a shortage, and
the impact of a shortage may differ between products and
between stakeholders. Further research is needed to provide
more insight into which signals have led to a shortage as well
as the impact of these shortages at population and individual
levels.
Two recent developments may narrow the observed
information gap. First, the definition of a drug shortage recently
became more uniform for MAHs. At an European level, MAHs
together with all other organizations in the pharmaceutical
supply chain agreed in 2016 on the definition of a suspected drug
shortage as: “the inability of a community or hospital pharmacy,
as a result of factors beyond their control, to supply a medicinal
product to a patient within a defined period, for example 72 h”
(AESGP et al., 2017. Also, Dutch authorities agreed on a broader
definition of a shortage in 2017: “an interruption of availability
of a medicinal product that is a burden for patients and where the
burden is greater than is the case for regular (generic) substitution”
(Dutch Government, Ministry of Health, Welfare and Sport,
2017). Both agreements may lead to more similarity in signals
to authorities and to pharmacy practice. Second, MAHs can
report to the newly established Medicine Shortages and Defects
Notification Center of the Dutch authorities since 2017. This
center enables MAHs to report at a central point, therefore
providing a quicker and more complete overview to authorities.
Future research is needed to examine the impact of these
developments.
CONCLUSIONS
Authorities and pharmacy practice were informed
on drug shortages differently with little overlap. In
order to gain maximum insight in drug shortages at
a national level combining data from both authorities
and pharmacy practice seems to be necessary. No single
source can give a complete picture. Moreover, the finding
that authorities were informed later than pharmacy
practice, raises concerns in terms of opportunities for
authorities to assist practice to sort out solutions for drug
shortages.
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